File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of selective serotonin reuptake inhibitors in children and adolescents

TitleUse of selective serotonin reuptake inhibitors in children and adolescents
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2004
PublisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/
Citation
Drug Safety, 2004, v. 27 n. 13, p. 991-1000 How to Cite?
AbstractDepression is a serious condition, associated with considerable morbidity and mortality; selective serotonin reuptake inhibitors (SSRIs) were commonly used in its treatment in child and adolescent psychiatry until recently. In the wake of the recent UK Committee on Safety of Medicines (CSM) advice, we conducted a rapid review of current available information on SSRIs and suicidality (suicidal ideation, self-harm and suicide attempt) in children and adolescents from clinical trials and epidemiological studies. There is insufficient safety information from the randomised controlled trials to confirm a definite association between SSRIs and suicidality. Furthermore, analysis of suicide and antidepressant prescribing trends in three countries and a large case-control study do not support the hypothesis that there is a link between use of SSRIs and death caused by suicide. Regulatory agencies and the media should have strict guidelines for the management of information relating to the treatment of this condition so that clinicians can make properly informed decisions. We suggest clinical guidelines for managing depression in children and adolescents. SSRIs should not be considered for use as first-line treatment in mild or moderate depression of childhood, where psychological interventions such as cognitive behaviour therapy or interpersonal therapy are the mainstay. SSRIs should be considered when there is severe depression that does not respond to psychological interventions; when the child is suicidal and is admitted as an inpatient, is severely depressed or has bipolar depression despite adequate doses of mood-stabilisation agents; or when the child or family prefers pharmacotherapy to psychological interventions and gives informed consent. Local bodies of clinicians or peer groups should agree protocols and acceptable guidelines, taking into consideration the type of patients being assessed, the availability of nonpharmacological intervention, and the benefit-risk ratio of the pharmacological intervention. It is important that parents (and patients when possible) be given accurate information regarding the current controversy over SSRI prescribing. More research into the use of SSRIs in childhood depression is urgently required.
Persistent Identifierhttp://hdl.handle.net/10722/132889
ISSN
2015 Impact Factor: 3.206
2015 SCImago Journal Rankings: 1.359
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, ICKen_HK
dc.contributor.authorBesag, FMCen_HK
dc.contributor.authorSantosh, PJen_HK
dc.contributor.authorMurray, MLen_HK
dc.date.accessioned2011-04-04T07:57:49Z-
dc.date.available2011-04-04T07:57:49Z-
dc.date.issued2004en_HK
dc.identifier.citationDrug Safety, 2004, v. 27 n. 13, p. 991-1000en_HK
dc.identifier.issn0114-5916en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132889-
dc.description.abstractDepression is a serious condition, associated with considerable morbidity and mortality; selective serotonin reuptake inhibitors (SSRIs) were commonly used in its treatment in child and adolescent psychiatry until recently. In the wake of the recent UK Committee on Safety of Medicines (CSM) advice, we conducted a rapid review of current available information on SSRIs and suicidality (suicidal ideation, self-harm and suicide attempt) in children and adolescents from clinical trials and epidemiological studies. There is insufficient safety information from the randomised controlled trials to confirm a definite association between SSRIs and suicidality. Furthermore, analysis of suicide and antidepressant prescribing trends in three countries and a large case-control study do not support the hypothesis that there is a link between use of SSRIs and death caused by suicide. Regulatory agencies and the media should have strict guidelines for the management of information relating to the treatment of this condition so that clinicians can make properly informed decisions. We suggest clinical guidelines for managing depression in children and adolescents. SSRIs should not be considered for use as first-line treatment in mild or moderate depression of childhood, where psychological interventions such as cognitive behaviour therapy or interpersonal therapy are the mainstay. SSRIs should be considered when there is severe depression that does not respond to psychological interventions; when the child is suicidal and is admitted as an inpatient, is severely depressed or has bipolar depression despite adequate doses of mood-stabilisation agents; or when the child or family prefers pharmacotherapy to psychological interventions and gives informed consent. Local bodies of clinicians or peer groups should agree protocols and acceptable guidelines, taking into consideration the type of patients being assessed, the availability of nonpharmacological intervention, and the benefit-risk ratio of the pharmacological intervention. It is important that parents (and patients when possible) be given accurate information regarding the current controversy over SSRI prescribing. More research into the use of SSRIs in childhood depression is urgently required.en_HK
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/en_HK
dc.relation.ispartofDrug Safetyen_HK
dc.subjectChemicals And Cas Registry Numbersen_US
dc.titleUse of selective serotonin reuptake inhibitors in children and adolescentsen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, ICK: wongick@hku.hken_HK
dc.identifier.authorityWong, ICK=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2165/00002018-200427130-00002en_HK
dc.identifier.pmid15471506-
dc.identifier.scopuseid_2-s2.0-8444236333en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8444236333&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue13en_HK
dc.identifier.spage991en_HK
dc.identifier.epage1000en_HK
dc.identifier.isiWOS:000225035400002-
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridWong, ICK=7102513915en_HK
dc.identifier.scopusauthoridBesag, FMC=7004367676en_HK
dc.identifier.scopusauthoridSantosh, PJ=6701465826en_HK
dc.identifier.scopusauthoridMurray, ML=7403583537en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats